Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for kids with kidney disease: experimental vitamin d pill enters trial

NCT ID NCT07494045

Not yet recruiting Disease control Sponsor: OPKO Health, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an extended-release vitamin D capsule (CTAP101) in 40 children aged 8 to 17 with stage 3 or 4 chronic kidney disease, secondary hyperparathyroidism, and low vitamin D. Participants take one capsule daily at bedtime for 8 weeks. The goal is to see how the body processes the drug and whether it is safe and tolerable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CKD STAGE 3 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease secondary hyperparathyroidism vitamin D deficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CKD STAGE 3 CKD STAGE 4 SECONDARY HYPERPARATHYROIDISM VDI

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • OPKO Site

    Kansas City, Missouri, 64108, United States

    Contact Email: •••••@•••••

  • OPKO Site

    Columbus, Ohio, 43205, United States

    Contact Email: •••••@•••••

  • OPKO Site

    Philadelphia, Pennsylvania, 19104, United States

    Contact Email: •••••@•••••

  • OPKO Site

    Greenville, South Carolina, 29615, United States

    Contact Email: •••••@•••••

  • OPKO Site

    Madison, Wisconsin, 53562, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.